BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Ríos-Ríos WJ, Sosa-Luis SA, Torres-Aguilar H. Current advances in using tolerogenic dendritic cells as a therapeutic alternative in the treatment of type 1 diabetes. World J Diabetes 2021; 12(5): 603-615 [PMID: 33995848 DOI: 10.4239/wjd.v12.i5.603]
URL: https://www.wjgnet.com/1948-9358/full/v12/i5/603.htm
Number Citing Articles
1
Caitlin N. Suire, Mangesh D. Hade. Extracellular Vesicles in Type 1 Diabetes: A Versatile ToolBioengineering 2022; 9(3): 105 doi: 10.3390/bioengineering9030105
2
Shiva Alipour, Tohid Kazemi, Mohammad Reza Sadeghi, Javad Ahmadian Heris, Javad Masoumi, Bahar Naseri, Elham Baghbani, Sepideh Sohrabi, Behzad Baradaran. Glyburide-treated human monocyte-derived dendritic cells loaded with insulin represent tolerogenic features with anti-inflammatory responses and modulate autologous T cell responses in vitroInternational Immunopharmacology 2024; 126: 111230 doi: 10.1016/j.intimp.2023.111230
3
Irina Buckle, Josephine M. Forbes. Type 1 Diabetes in 2023 - From Real Practice to Open Questions2023;  doi: 10.5772/intechopen.108528
4
Nélio A.J. Oliveira, Handan Sevim. Dendritic Cell Differentiation from Human Induced Pluripotent Stem Cells: Challenges and ProgressStem Cells and Development 2022; 31(9-10): 207 doi: 10.1089/scd.2021.0305
5
Liu YANG, Xuejiao ZHANG, Qing LIU, Yan WEN, Qing WANG. Update on the ZNT8 epitope and its role in the pathogenesis of type 1 diabetesMinerva Endocrinology 2023; 48(4) doi: 10.23736/S2724-6507.22.03723-X
6
Khalid Siddiqui, Shaik Sarfaraz Nawaz. Exploration of Immune Targets for Type 1 Diabetes and Latent Autoimmune Disease ImmunotherapyImmunoTargets and Therapy 2023; : 91 doi: 10.2147/ITT.S417917
7
Nick Giannoukakis. Tolerogenic dendritic cells in type 1 diabetes: no longer a conceptFrontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1212641